Impairment of muscarinic transmission in transgenic APPswe/PS1dE9 mice

Neurobiology of Aging

Volumn 29, Issue 3, 2008, Pages 368-378

  Machova E ^a   Jakubik J ^a   Michal, P ^a   Oksman, M ^b   Iivonen, H ^b   Tanila, H ^b,c   Dolezal V ^a  

^a INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Acetylcholinesterase; Butyrylcholinesterase; Choline acetyltransferase; Cholinergic neurotransmission; G protein coupling; Muscarinic receptors; Transgenic mouse; Vesicular acetylcholine transporter

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID; CARBACHOL; CHOLINE ACETYLTRANSFERASE; CHOLINESTERASE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MUSCARINIC RECEPTOR; VESICULAR ACETYLCHOLINE TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLINERGIC TRANSMISSION; COGNITION; CONTROLLED STUDY; ENZYME ACTIVITY; GENOTYPE; GROUPS BY AGE; MOUSE; NONHUMAN; PARIETAL LOBE; PRIORITY JOURNAL; TRANSGENIC MOUSE; WILD TYPE;

ACETYLCHOLINESTERASE; AGE FACTORS; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; MICE; MUTATION; N-METHYLSCOPOLAMINE; PIPERIDINES; PRESENILIN-1; PROTEIN BINDING; RECEPTORS, MUSCARINIC; SYNAPTIC TRANSMISSION; VESICULAR ACETYLCHOLINE TRANSPORT PROTEINS;

EID: 38949177729     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2006.10.029     Document Type: Article

References (72)

1. Aucoin J.S., Jiang P., Aznavour N., Tong X.K., Buttini M., Descarries L., Hamel E., Aucoin J.S., Jiang P., Aznavour N., Tong X.K., Buttini M., Descarries L., and Hamel E. Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer's disease. Neuroscience 132 (2005) 73-86
2. Bartus R.T. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol. 163 (2000) 495-529
3. Bartus R.T., Dean R.L., Beer B., and Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 217 (1982) 408-414
4. Berrard S., Varoqui H., Cervini R., Israel M., Mallet J., and Diebler M.F. Coregulation of two embedded gene products, choline acetyltransferase and the vesicular acetylcholine transporter. J. Neurochem. 65 (1995) 939-942
5. Berse B., and Blusztajn J.K. Coordinated up-regulation of choline acetyltransferase and vesicular acetylcholine transporter gene expression by the retinoic acid receptor alpha, cAMP, and leukemia inhibitory factor/ciliary neurotrophic factor signaling pathways in a murine septal cell line. J. Biol. Chem. 270 (1995) 22101-22104
6. Blusztajn J.K., and Berse B. The cholinergic neuronal phenotype in Alzheimer's disease. Metab. Brain Dis. 15 (2000) 45-64
7. Bowen D.M., Smith C.B., White P., and Davison A.N. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99 (1976) 459-496
8. Brandon E.P., Mellott T., Pizzo D.P., Coufal N., D'Amour K.A., Gobeske K., Lortie M., Lopez-Coviella I., Berse B., Thal L.J., Gage F.H., and Blusztajn J.K. Choline transporter 1 maintains cholinergic function in choline acetyltransferase haploinsufficiency. J. Neurosci. 24 (2004) 5459-5466
9. Buxbaum J.D., Oishi M., Chen H.I., Pinkas-Kramarski R., Jaffe E.A., Gandy S.E., and Greengard P. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10075-10078
10. Capsoni S., Giannotta S., and Cattaneo A. Beta-amyloid plaques in a model for sporadic Alzheimer's disease based on transgenic anti-nerve growth factor antibodies. Mol. Cell Neurosci. 21 (2002) 15-28
11. Capsoni S., Ugolini G., Comparini A., Ruberti F., Berardi N., and Cattaneo A. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 6826-6831
12. Cervini R., Houhou L., Pradat P.F., Bejanin S., Mallet J., and Berrard S. Specific vesicular acetylcholine transporter promoters lie within the first intron of the rat choline acetyltransferase gene. J. Biol. Chem. 270 (1995) 24654-24657
13. Custers F.G., Leysen J.E., Stoof J.C., and Herscheid J.D. Vesamicol and some of its derivatives: questionable ligands for selectively labelling acetylcholine transporters in rat brain. Eur. J. Pharmacol. 338 (1997) 177-183
14. Davies P., and Maloney A.J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2 (1976) 1403
15. DeKosky S.T., Ikonomovic M.D., Styren S.D., Beckett L., Wisniewski S., Bennett D.A., Cochran E.J., Kordower J.H., and Mufson E.J. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol. 51 (2002) 145-155
16. Dolezal V., and Kasparova J. Beta-amyloid and cholinergic neurons. Neurochem. Res. 28 (2003) 499-506
17. Duysen E.G., Stribley J.A., Fry D.L., Hinrichs S.H., and Lockridge O. Rescue of the acetylcholinesterase knockout mouse by feeding a liquid diet; phenotype of the adult acetylcholinesterase deficient mouse. Brain Res. Dev. Brain Res. 137 (2002) 43-54
18. Efange S.M., Garland E.M., Staley J.K., Khare A.B., and Mash D.C. Vesicular acetylcholine transporter density and Alzheimer's disease. Neurobiol. Aging 18 (1997) 407-413
19. Ellman G.L., Courtney K.D., Andres V.J., and Feather-Stone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7 (1961) 88-95
20. Erickson J.D., Varoqui H., Schafer M.K., Modi W., Diebler M.F., Weihe E., Rand J., Eiden L.E., Bonner T.I., and Usdin T.B. Functional identification of a vesicular acetylcholine transporter and its expression from a "cholinergic" gene locus. J. Biol. Chem. 269 (1994) 21929-21932
21. Fonnum F. Radiochemical micro assays for the determination of choline acetyltransferase and acetylcholinesterase activities. Biochem. J. 115 (1969) 465-472
22. Francis P.T., Palmer A.M., Sims N.R., Bowen D.M., Davison A.N., Esiri M.M., Neary D., Snowden J.S., and Wilcock G.K. Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment. N. Engl. J. Med. 313 (1985) 7-11
23. Francis P.T., Palmer A.M., Snape M., and Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 66 (1999) 137-147
24. Frolich L. The cholinergic pathology in Alzheimer's disease-discrepancies between clinical experience and pathophysiological findings. J. Neural. Transm. 109 (2002) 1003-1013
25. Gau J.T., Steinhilb M.L., Kao T.C., D'Amato C.J., Gaut J.R., Frey K.A., and Turner R.S. Stable beta-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice. Am. J. Pathol. 160 (2002) 731-738
26. German D.C., Yazdani U., Speciale S.G., Pasbakhsh P., Games D., and Liang C.L. Cholinergic neuropathology in a mouse model of Alzheimer's disease. J. Comp. Neurol. 462 (2003) 371-381
27. Greig N.H., Utsuki T., Ingram D.K., Wang Y., Pepeu G., Scali C., Yu Q.S., Mamczarz J., Holloway H.W., Giordano T., Chen D., Furukawa K., Sambamurti K., Brossi A., and Lahiri D.K. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 17213-17218
28. Haass C., and Steiner H. Protofibrils, the unifying toxic molecule of neurodegenerative disorders?. Nat. Neurosci. 4 (2001) 859-860
29. Hartmann J., Erb C., Ebert U., Baumann K.H., Popp A., Konig G., and Klein J. Central cholinergic functions in human amyloid precursor protein knock-in/presenilin-1 transgenic mice. Neuroscience 125 (2004) 1009-1017
30. Hedreen J.C., Bacon S.J., and Price D.L. A modified histochemical technique to visualize acetylcholinesterase-containing axons. J. Histochem. Cytochem. 33 (1985) 134-140
31. Holler T., Berse B., Cermak J.M., Diebler M.F., and Blusztajn J.K. Differences in the developmental expression of the vesicular acetylcholine transporter and choline acetyltransferase in the rat brain. Neurosci. Lett. 212 (1996) 107-110
32. Hoyer S. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp. Gerontol. 35 (2000) 1363-1372
33. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., and Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274 (1996) 99-102
34. Hu L., Wong T.P., Cote S.L., Bell K.F., and Cuello A.C. The impact of Abeta-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in alzheimer's disease-like transgenic mice. Neuroscience 121 (2003) 421-432
35. Ikarashi Y., Harigaya Y., Tomidokoro Y., Kanai M., Ikeda M., Matsubara E., Kawarabayashi T., Kuribara H., Younkin S.G., Maruyama Y., and Shoji M. Decreased level of brain acetylcholine and memory disturbance in APPsw mice. Neurobiol. Aging 25 (2004) 483-490
36. Jakubik J., Bacakova L., el-Fakahany E.E., and Tucek S. Subtype selectivity of the positive allosteric action of alcuronium at cloned M1-M5 muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 274 (1995) 1077-1083
37. Jakubik J., El-Fakahany E.E., and Dolezal V. Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M1 and M2 muscarinic acetylcholine receptors. Mol. Pharmacol. (2006)
38. Jankowsky J.L., Melnikova T., Fadale D.J., Xu G.M., Slunt H.H., Gonzales V., Younkin L.H., Younkin S.G., Borchelt D.R., and Savonenko A.V. Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J. Neurosci. 25 (2005) 5217-5224
39. Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., Copeland N.G., Lee M.K., Younkin L.H., Wagner S.L., Younkin S.G., and Borchelt D.R. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 13 (2004) 159-170
40. Jankowsky J.L., Slunt H.H., Ratovitski T., Jenkins N.A., Copeland N.G., and Borchelt D.R. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 17 (2001) 157-165
41. Jope R.S., Song L., Li X., and Powers R. Impaired phosphoinositide hydrolysis in Alzheimer's disease brain. Neurobiol. Aging 15 (1994) 221-226
42. Jope R.S., Song L., and Powers R.E. Cholinergic activation of phosphoinositide signaling is impaired in Alzheimer's disease brain. Neurobiol. Aging 18 (1997) 111-120
43. Joseph J.A., Cutler R., and Roth G.S. Changes in G protein-mediated signal transduction in aging and Alzheimer's disease. Ann. N.Y. Acad. Sci. 695 (1993) 42-45
44. Kelly J.F., Furukawa K., Barger S.W., Rengen M.R., Mark R.J., Blanc E.M., Roth G.S., and Mattson M.P. Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 6753-6758
45. Kenakin T. Principles: receptor theory in pharmacology. Trends Pharmacol. Sci. 25 (2004) 186-192
46. Klein W.L., Krafft G.A., and Finch C.E. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci. 24 (2001) 219-224
47. Kuhl D.E., Koeppe R.A., Snyder S.E., Minoshima S., Frey K.A., and Kilbourn M.R. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses. Ann. Neurol. 59 (2006) 13-20
48. Li X., Greenwood A.F., Powers R., and Jope R.S. Effects of postmortem interval, age, and Alzheimer's disease on G-proteins in human brain. Neurobiol. Aging 17 (1996) 115-122
49. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
50. Mattson M.P., and Pedersen W.A. Effects of amyloid precursor protein derivatives and oxidative stress on basal forebrain cholinergic systems in Alzheimer's disease. Int. J. Dev. Neurosci. 16 (1998) 737-753
51. McLaughlin M., Ross B.M., Milligan G., McCulloch J., and Knowler J.T. Robustness of G proteins in Alzheimer's disease: an immunoblot study. J. Neurochem. 57 (1991) 9-14
52. Meier-Ruge W., Bertoni-Freddari C., and Iwangoff P. Changes in brain glucose metabolism as a key to the pathogenesis of Alzheimer's disease. Gerontology 40 (1994) 246-252
53. Messier C., and Gagnon M. Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes. Behav. Brain Res. 75 (1996) 1-11
54. Mesulam M.M. The cholinergic innervation of the human cerebral cortex. Prog. Brain Res. 145 (2004) 67-78
55. Michal P., Lysikova M., and Tucek S. Dual effects of muscarinic M(2) acetylcholine receptors on the synthesis of cyclic AMP in CHO cells: dependence on time, receptor density and receptor agonists. Br. J. Pharmacol. 132 (2001) 1217-1228
56. Nitsch R.M., Slack B.E., Wurtman R.J., and Growdon J.H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258 (1992) 304-307
57. Oksman M., Iivonen H., Hogyes E., Amtul Z., Penke B., Leenders I., Broersen L., Lutjohann D., Hartmann T., and Tanila H. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol. Dis. 23 (2006) 563-572
58. Pepeu G. Overview and perspective on the therapy of Alzheimer's disease from a preclinical viewpoint. Prog. Neuropsychopharmacol. Biol. Psychiatry 25 (2001) 193-209
59. Perry E.K., Gibson P.H., Blessed G., Perry R.H., and Tomlinson B.E. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J. Neurol. Sci. 34 (1977) 247-265
60. Perry E.K., Perry R.H., Blessed G., and Tomlinson B.E. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1 (1977) 189
61. Peterson G.L. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal. Biochem. 83 (1977) 346-356
62. Ruberti F., Capsoni S., Comparini A., Di Daniel E., Franzot J., Gonfloni S., Rossi G., Berardi N., and Cattaneo A. Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy. J. Neurosci. 20 (2000) 2589-2601
63. Savonenko A., Xu G.M., Melnikova T., Morton J.L., Gonzales V., Wong M.P., Price D.L., Tang F., Markowska A.L., and Borchelt D.R. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol. Dis. 18 (2005) 602-617
64. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81 (2001) 741-766
65. Sims N.R., Bowen D.M., and Davison A.N. [14C]Acetylcholine synthesis and carbon 14C dioxide production from [U-14C]glucose by tissue prisms from human neocortex. Biochem. J. 196 (1981) 867-876
66. Snowdon D.A. Healthy aging and dementia: findings from the Nun Study. Ann. Intern. Med. 139 (2003) 450-454
67. Tsang S.W., Lai M.K., Kirvell S., Francis P.T., Esiri M.M., Hope T., Chen C.P., and Wong P.T. Impaired coupling of muscarinic M(1) receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease. Neurobiol. Aging (2005)
68. Tucek S., Michal P., and Vlachova V. Modelling the consequences of receptor-G-protein promiscuity. Trends Pharmacol. Sci. 23 (2002) 171-176
69. Urban J.D., Clarke W.P., von Zastrow M., Nichols D.E., Kobilka B.K., Weinstein H., Javitch J.A., Roth B.L., Christopoulos A., Sexton P., Miller K., Spedding M., and Mailman R.B. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. (2006)
70. Wang J., Tanila H., Puolivali J., Kadish I., and van Groen T. Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice. Neurobiol. Dis. 14 (2003) 318-327
71. Wong T.P., Debeir T., Duff K., and Cuello A.C. Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J. Neurosci. 19 (1999) 2706-2716
72. Xie W., Stribley J.A., Chatonnet A., Wilder P.J., Rizzino A., McComb R.D., Taylor P., Hinrichs S.H., and Lockridge O. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase. J. Pharmacol. Exp. Ther. 293 (2000) 896-902